1st NordiQC Conference on Standardization in Applied Immunohistochemistry 2013 1



Similar documents
Articles. Nordic Immunohistochemical Quality Control (NordiQC) - An Organization for External Quality Assurance. Mogens Vyberg, MD

PATHOLOGY. HercepTestTM. Product Information

HER2 Testing in Breast Cancer

IHC Service Center. Department of Medicine

A 70-year old Man with Pleural Effusion

Clinical Histology Procedure Histo03.01 Automated Immunohistochemical Staining Utilizing the Ventana Benchmark Instrument

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Interpretation Guide for VENTANA anti-her2/neu (4B5)

March 19, Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

ab StayBlue/AP Plus Stain Kit Instructions for Use An immunohistochemical chromogen substrate for staining tissue sections

Clinical Histology Procedure histo13.01 Automated Immunohistochemical Staining Utilizing the Bond III Instrument

Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?

VENTANA Digital Pathology. Reliable. Efficient. Comprehensive.

Immunohistochemistry. Services & Products. Indivumed GmbH Falkenried 88, Bldg. D Hamburg Germany

10/06/2013. Commentary. The best way to achieve optimal treatment of today s patients is to ensure the availability of

Regulatory Issues in Genetic Testing and Targeted Drug Development

FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND

How To Use Calretinin

Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

BREAST CANCER PATHOLOGY

JOINT COMMISSION INTERNATIONAL ACCREDITATION STANDARDS FOR. 2nd Edition

How To Use A Breast Cancer Test To Help You Choose Chemotherapy

Laboratory Testing for Her2 Status in Breast Cancer

Practical Effusion Cytology

Sutter Health Support Services Shared Laboratory Position Description. Incumbent: Laboratory Date: October 23, 2006 Written By: Michele Leonard

How To Get A Cell Print

SMF Awareness Seminar 2014

Fixation and Other Pre-Analytical Factors

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

Your Guide to the Breast Cancer Pathology Report

Product Datasheet and Instructions for Use

Outline. 1. Experiment. 2. Sample analysis and storage. 3. Image analysis and presenting data. 4. Probemaker

IHC Nuclear Image Analysis. User s Guide

EDUCATION. HercepTest TM. Interpretation Manual Breast Cancer

HER2. Improved Quality and Efficiency FISH. HER2 IQFISH pharmdx

DETERMINATION OF HER2 STATUS IN BREAST CANCER PATIENTS BY TWO METHODS: REAL-TIME QUANTITATIVE PCR (QPCR) AND IMMUNOENZIMATIC ASSAY (EIA)

BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Bronson Methodist Hospital: A systematic approach to validating xylene free processing on the Leica PELORIS tissue processor.

1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages

NAACLS Standards for Accredited and Approved Programs. Adopted 2012, Revised 9/2013, 1/2014, 4/2014, 10/2014, 11/2014

IBCSG Tissue Bank Policy

TFE3 (MRQ-37) Rabbit Monoclonal Antibody PRODUCT AVAILABILITY SYMBOL DEFINITIONS INTENDED USE PRINCIPLES AND PROCEDURES SUMMARY AND EXPLANATION

ab TripleStain IHC Kit: M&M&R on rodent tissue (DAB, DAB/Ni & AP/Red)

BRCA and Breast/Ovarian Cancer -- Analytic Validity Version

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Measurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center

Quality Requirements of a Point of Care Testing Service

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE

Understanding your pathology report

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts

FDA Regulation of Genetic Tests. Steven Gutman, M.D. Office of In Vitro Diagnostics

HER2 FISH pharmdx. Assay Kit

KMS-Specialist & Customized Biosimilar Service

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Medical Laboratory Technology Program. Student Learning Outcomes & Course Descriptions with Learning Objectives

We Believe the Possibilities. Delphic AP

Immunohistochemical classification of malignant lymphomas

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Your Guide to the Breast Cancer Pathology Report

Standardisation of breast cancer pathology report. Gerd JACOMEN Pathology Breast Clinic AZ St Maarten Duffel/Mechelen Breast Clinic Voorkempen Malle

Notes on titering antibodies

Preparation "Clinical Laboratory Technologist and Technician Overview"

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

The Dako CoverStainer. t Vivantes. n Germany

Human Luteinizing Hormone (LH) Custom Kit

Tissue Cross-Reactivity of QRX-111 with Human, Cynomolgus Monkey and Rat Tissues in Vitro

Principles of Immunohistochemistry Queen s Laboratory For Molecular Pathology

The Diagnosis of Cancer in the Pathology Laboratory

OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ

Ep-CAM/Epithelial Specific Antigen (MOC-31)

Genetic testing. The difference diagnostics can make. The British In Vitro Diagnostics Association

USING CLSI GUIDELINES TO PERFORM METHOD EVALUATION STUDIES IN YOUR LABORATORY

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

What is special about a stain, and why do we call some stains

Helen Joseph Breast Care Clinic - Johannesburg, South Africa

P4 Distribution of Cetuximab in Models of Human Lung Cancer

FRIEND TO FRIEND CPT CODES Diagnostic digital breast tomosynthesis, unilateral (list separately in addition to code for primary procedure)

III II II III. ge: /ears sex: Male Access

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Digital Pathology Image Analysis with Definiens

Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)

Delphic AP. Designer software for your pathology workflow. We Believe the Possibilities.

Parathyroid Hormone (PTH) (MRQ- 31)

Immunohistochemistry of soft tissue tumors

Urinalysis Compliance Tools. POCC Webinar January 19, 2011 Dr. Susan Selgren

Transcription:

Hotel Hvide Hus, Aalborg, 4 th 7 th June 2013 Prof. Mogens Vyberg, NordiQC director Serial sections stained for Estrogen receptor Breast cancers stained for Estrogen receptor Why? 5 6 2013 1

Breast cancers stained for CK-HMW Breast cancers stained for CK-HMW CK5 34BE12 HIER+PROT Lab. C Lab. C 34BE12 HIER IHC quality problem Immunohistochemistry Staining patterns and quality varies between different laboratories - depending on the expertise and individual selection of reagents and methods Different antibodies, visualization systems, chromogenes, platforms and guide lines give different results Internal quality control will often not identify a poorly calibrated IHC system or varying quality of products giving insufficient or aberrant staining results External quality assessment is mandatory 9 Processing decalcification Tissue type, dimensions, biological variation (tumour dediff.) cauterization Interpretation quantification pos./neg. def. -cut-off level panels algorithms Sections thickness drying storage Fixation delay, time, type, volume Pre-treatment proteolysis, HIER, time, temp, ph Platform manual stainer type Visualization system sensitivity, specificity enhancement Reporting diagnostic context Control internal/external critical stain quality indicators Primary antibody clone, dilution buffer, time, temp Analytic Chromogene sensitivity, Immunohistochemistry External Quality Assessment Processing decalcification Tissue type, dimensions, biological variation (tumour dediff.) cauterization Fixation delay, time, type, volume Interpretation quantification pos./neg. def. -cut-off level panels algorithms Preanalytic Postanalytic Pre- EQA analytic Sections thickness drying stainer storage Postanalytic Pre-treatment proteolysis, HIER, time, temp, ph Platform manual type Visualization system sensitivity, specificity enhancement Reporting diagnostic context Control internal/external critical stain quality indicators Primary antibody clone, dilution buffer, time, temp Analytic Chromogene sensitivity, Nordic immunohistochemical Quality Control Founded 2003 by Nordic pathologists Independent, scientific, not-for-profit organisation Institute of Pathology, Aalborg University Hospital General module: 3 runs/year 15-18 different markers Breast cancer IHC module: 2 runs HER-2, ER/PR, Ki/E-Cad HER-2 ISH module: 2 runs/year BRISH, FISH 12 2013 2

NordiQC participants NordiQC Assessments ~ 40 countries Central assessment with consensus between experienced pathologists and histotechnologists Nordic countries Correlate staining results with central protocol parameters in order to identify Successful and less successful Abs Appropriate and inappropriate protocol settings Staining platform issues Reliable control tissues Publish general results on an open website: www.nordiqc.org 2004 2006 2008 2010 2012 General Breast ca. IHC HER-2 ISH E-mail individual results to the participants Specific explanations for insufficient results Tailored recommendations for improvement 14 NordiQC Assessments Assessments > 50 runs = > 30,000 slides = > 150,000 tissue sections = > 1,500,000 bits of protocol info. Results of NordiQC recommendations 419 advices for 11 markers No. Improved % Positive 268 195 73 Negative 151 21 14 www.nordiqc.org 16 NordiQC EQA: Estrogen Receptor 2003-11 200 HER-2 staining results in 10 runs % 180 160 140 articipants No. pa 120 100 80 84 72 79 81 74 90 60 40 45 20 0 8 10 13 B1 B3 B5 B7 B8 B10 B11 2003 2006 RUN 2009 2011 PASS RATE (%) No. OF PARTICIPANTS 2013 3

Economic impact of HER-2 test inaccuracy IHC External Quality Assessment Application of NordiQC test results 2008-12 in an economic model for the US population (unpublished) Approved IVD Nonapproved IVD Total Number of tests 1145 (%) 558 (33%) 1703 Pooled FN + FP rates 11% 30% Total costs $M 14 $M 55 $M 69 About 30% of all IHC stains assessed by NordiQC are still insufficient! New labs New antibodies, techniques, platforms Increasing demands How many IHC stains produced by labs not participating in an EQA scheme are insufficient? How many scientific publications are based on insufficient IHC stains? 19 Optimized Ki staining how to count? Ki staining in two labs - no sense in counting ROI - Hotspot or average? Cut off for staining intensity? Enjoy your stay in Aalborg Hormone receptors HER-2 Ki Gene profiling in relation to IHC Mutation specific protein markers Haematopathology markers EQA programmes Central parameters in optimization / standardization Image analysis and stereology in relation to IHC Handouts are available on the website 24 2013 4

KUNSTEN Museum of Modern Art Dinner in Robber s Camp Thursday Bus dept. 18:00 Name badges must be worn at all times Tickets presented at bus departure Reception Wednesday 18:00 19:30 Name badges must be worn at all times Icelandic artist Olafur Eliasson 25 Hotel Hvide Hus, Aalborg, 4 th 7 th June 2013 Prof. Mogens Vyberg, NordiQC director Welcome to Aalborg 2013 5